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Treatment offresh human leukaemia cells with actinomycin D
enhances their lysability by natural killer cells
H.W.L. Ziegler-Heitbrock, J. Erhardt and G. Riethmiiller
Institutefor Immunology, Schillerstrasse 42, 8000 Muinchen 2, FRG
Summary Human leukaemia cells isolated from peripheral blood were employed as targets for natural killer
(NK) cells obtained from healthy donors and the effect of pretreatment ofleukaemia cells with Actinomycin D
on lysability was analysed in a chromium release assay. In 8/14 leukaemia cell samples a substantial
enhancement of specific release could be repeatedly obtained by exposure of leukaemia targets to
Actinomycin D for 4h. The phenomenon was seen both with interferon-treated and untreated NK cells and
could be demonstrated with fresh, as well as, liquid nitrogen stored leukaemia cells. In contrast, lysis of two
leukaemia cell lines could not be further enhanced and no release was seen from normal lymphocyte targets
or mitogen-induced blasts. Cold target inhibition studies indicate that enhanced killing is mediated by the
same kind of natural killer cell, which is active against the Molt4 and K562 leukaemia cell lines.
Attempts to enhance cell-mediated lysis of human
leukaemia cells initially focused on the effector
cells, using in vitro stimulation techniques with
irradiated leukaemia cells, allogeneic cells or
interferon (IFN) (Khare et al., 1980; Moore et al.,
1982; Lee & Oliver, 1978; Pattengale et al., 1982;
Taylor, 1981; Zarling et al., 1976; 1978; 1979).
Recent studies with various drugs including
cytostatics (Schlager & Ohanian, 1979; Schlager,
1982; Collins, 1981; Kunkel & Welsh, 1981)
demonstrated that treatment of the tumour targets
can modulate their susceptibility to lysis.
Schlager and Ohanian (1979) reported on
enhanced complement-dependent lysis induced by
Actinomycin D in a guinea pig hepatoma (Schlager
& Ohanian, 1979) and an enhanced T cell-mediated
lysis induced by mitomycin C treatment of P815
mouse tumour cells (Schlager, 1982).
Further, murine fibroblasts are minimally or not
at all lysed by NK cells. Treatment of the
fibroblasts with cycloheximide or Actinomycin D,
however, induces strong NK cell mediated lysis.
(Collins et al., 1981; Kunkel & Welsh, 1981). In
vitro derived carcinogen-transformed fibroblasts
were highly NK sensitive, but again became
resistant when passaged in mice with high NK cell
activity (Collins et al., 1981).
Therefore, we wondered whether freshly
explanted human leukaemia cells might exhibit a
resistance to NK cell-mediated lysis that could be
overcome by drug treatment of the tumour cells. In
fact, our data show that NK cell-mediated lysis of
fresh human leukaemia cells is enhanced by
treatment with Actinomycin D in addition to the
enhancement that occurs with IFN treatment of
effector cells.
Materials and methods
Cells
Peripheral blood from patients with acute
leukaemia or chronic myeloid leukaemia in blast
crisis (CML-BC) was obtained through courtesy of
Drs. B. Emmerich, Med. Klinik, Technische
Universitiit, Munich, H. Theml, Stiidtisches
Krankenhaus Muinchen-Schwabing, Munich, W.
Siegert, Medizinische Klinik III, Klinikum
GroBhadern, Munich and B. Netzel, Haunersches
Kinderspital, University Munich. Peripheral blood
mononuclear cells were obtained from healthy
young adult volunteer donors for use either as
effector cells or as control target cells.
Leukaemic blood cells (LBC) and peripheral
blood mononuclear cells (PBM) from normal
donors were prepared from heparinized blood,
diluted 1:2 with PBS and separated over a Ficoll-
hypaque density gradient (density 1.077, 30min,
800g) (B6yum, 1968). The PBM or LBC were
collected from the interface and washed x 3 with
PBS containing 2.5% heat inactivated foetal calf
serum (FCS). Cells were resuspended in RPMI1640
medium containing 10% FCS and
penicillin/streptomycin (RPMI/FCS) to be used in
subsequent tests. The leukaemic samples used in
this study all contained >85% leukaemic blasts.
Cell lines K562 (Lozzio et al., 1976) and Molt4
(Minowada et al., 1972) were maintained in
suspension culture and used in the log-phase of
growth. For preparation of PHA blast cells PBMs
at 106ml-1 in 5ml RPMI/FCS were cultured in
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upright No. 3013 tissue culture flasks (Falcon,
Oxnard, CA, USA) for 3-days in the presence of
optimal concentrations of PHA.
Storage of cells: Aliquots of 20-200 x 106 LBC or
PBM were frozen under controlled conditions in
the presence of 10% DMSO using a Planer PTC
200 machine (Planer, Sunberry-on-Thames, UK)
and stored in liquid nitrogen. Immediately before
use cells were rapidly thawed in a 37°C waterbath
and washed twice.
Interferon-activation of effector cells: Fresh or
cryopreserved PBM were adjusted to 4 x l06ml-1
and incubated at 370C for 1-2h in RPMI/FCS with
or without human fibroblast interferon ((IFN-fl),
300-500Uml- final concentration. This and all
other 370C incubations were performed in a
humidified 5% CO2 atmosphere. The IFN was
generously provided by Dr. von Eichborn,
Rentschler, Laupheim, FRG.
Drug treatment and radioactive labelling of target
cells: PBM and PHA-blasts from normal donors,
leukaemia cell lines or LBC were incubated at 1-
2 x 106mlP1 in RPMI/FCS in upright No. 3013
tissue culture flasks in the presence of various
concentrations of Actinomycin D (ActD) or
without the drug for 2h. Cells were spun down in
No. 2095 conical tubes (Falcon, Oxnard, CA, USA)
and the supernatant was removed except for 200p1.
To this 20p1 of Na51CrO4 with 5mCiml1 (New
England Nuclear, Dreieich, FRG) was added.
During the 1.5-2h period of labelling the cells were
resuspended every 20min. The targets were washed
x4 and adjusted to 105 cellsml-'. The total time
of drug treatment was 2h pretreatment plus the
labelling time.
Chromium release assay
One hundred p1 effector cells (2.5-10 x 106 cells and
serial dilutions) were mixed with 100p1 of the target
cell suspension in U-bottom microtiter plates in
triplicate. After centrifugation at 50g for 5min,
plates were incubated for 5.5h. Chromium release
was determined by counting 100p1 supernatant
aliquots in a y-counter. For spontaneous release
target cells were incubated with medium alone, for
total release with 5% Triton-x-100. Specific release
was calculated according to the formula
experimental release-spontaneous release 100
total release-spontaneous release
For cold target inhibition studies radiolabelled
leukaemia cells were admixed with 2-fold serial
dilutions of various unlabelled leukaemia cells and
with IFN-activated effector cells at a constant
effector-to-target (E:T) ratio of 50:1. Wells with
labelled and unlabelled targets alone were set up to
subtract protective effects on the spontaneous
release which were seen in some experiments.
Results and discussion
The effect of IFN pretreatment of effector cells on
NK lysis of human leukaemia cells was studied in
the first experiments (Table I). In Expt. 1
enhancement of lysis could be seen from 40.1% to
55.5% specific release at an E:T of 60:1. In Expt.
2, no lysis was seen without pretreatment at 40:1
E:T (-3.3%) but significant release (13.0%)
occurred after IFN treatment. These findings are in
agreement with earlier reports (Zarling et al., 1979;
Pattengale et al., 1982; Moore et al., 1982), where
IFN treatment of effector cells was shown to
enhance lysis of fresh leukaemia and lymphoma
cells. As shown in the same experiments with
untreated effector cells, pretreatment of leukaemic
cells with ActD resulted in enhanced lysis as well.
Enhancement, for instance, occurred from 40.1% to
59.0% after treatment with ActD at 1 pgml-I for
4h in Expt. 1, while in Expt. 2, ActD pretreatment
enhanced lysis from -3.3 to 17.1% specific release.
Since IFN activation of NK cells and
pretreatment of leukaemic cells with ActD might
affect the same population of leukaemia cells
resistant to lysis without either treatment, we
preincubated effector cells with and without IFN
and leukaemia cells with and without ActD.
Pretreatment of both effector cells and leukaemia
cells with IFN and ActD, respectively, resulted in
greater lysis than obtained with either treatment
alone, e.g., 55.2% for IFN pretreatment, 59.0% for
ActD pretreatment and 83.2% for both IFN and
ActD pretreatment in Expt. 1. Similar results were
seen in the other experiments with the same target
(Expts. 2 and 3) and with 2 other leukaemias
(Expts. 7 and 11). These findings suggest that ActD
renders an additional fraction of the leukaemia cells
susceptible to NK lysis, a fraction that is not lysed
within the time limits of the assay when IFN
activated NK cells are used. Thus the percentage of
fresh human leukaemia cells that can be lysed by
spontaneously cytotoxic cells is higher than
previously found. In all further experiments we
primarily used IFN pretreatment of effector cells to
obtain high specific release.
Representative experiments with the leukaemia
cells of 4 donors using IFN-activated killer cells are
shown in Figure 1 giving specific release at different
E:T ratios. For the Vg target (Figure IA) IFN
treatment of effector cells alone resulted in aTable I Effect ofActinomycin D on susceptibility of fresh human leukaemia cells to spontaneous cell-mediated lysis'
Specific release+s.d.4(%)
afterpretreatment ofeffector cells
-IFNs +IFN
Pretreatment oftarget cells Pretreatment oftarget cells
Exp. Effector E:T ActD6
Target cell no. cell ratio -ActD +ActD -ActD +ActD (igml-')
Vg*(ALL)' 1 Hb
2 Er
3 Di
4 Wa
5 Ro*
6 Ro*
Ri(CML-BC) 7 Ma
Ri* 8 Jo*
9 Ra
Sc(AML) 10 Fu
Sc* 11 Fu*
St*(ALL) 12 Wa
Ma
Bl*(AML) 13 Fi*
Ra*(AML) 14 Fi*
Kr*(CML-BC) 15 Zi*
Pra*(AMML) 16 He*
Su*(CML-BC) 17 Hb
Hu*(AMML) 18 Zi
Jo*
Mi*(AML) 19 Me*
Jo*
Rd*(AML) 20 Me*
Jo*
Rp(ALL) 21 Kr*
Li*(AML) 22 Zl*
Re*
Di*(PBM) 23 Jo*
Me*
Er*(PBM) 24 Wa*
Jo*
Jo*(PBM) 25 Ha
OS*(PHA-BL) 26 Jo*
Me*
Mn(PHA-BL) 27 OS*
Sa*
K562(CML-BC) 28 Mr*
cell line Ss*
29 Ss
Molt4(ALL) 30 Zi*
cell line Ss*
60:1
40:1
50:1
40:1
20:1
37.5:1
50:1
40:1
50:1
18:1
37.5:1
25:1
30:1
50:1
60:1
100:1
50:1
40:1
40:1
25:1
35:1
25:1
40:1
30:1
50:1
50:1
50:1
50:1
60:1
60:1
60:1
50:1
50:1
50:1
50:1
40:1
25:1
25:1
35:1
40:1
40:1
40.1+3.6 59.0+5.7
-3.3+8.4 17.1+6.0
-2.1+2.5 2.5+1.6
14.6+0.2 23.3+1.2
7.5+1.8 11.0+1.0
10.6+2.1
0.4+1.0 -1.9+2.0
29.6+0.9 13.8+0.8
22.6+3.2 15.2+ 1.5
55.5+1.7 83.2+4.7
13.0+3.4 37.9+3.8
4.1+1.0 23.4+1.9
13.6+3.5 42.2+0.2
20.7+3.8 47.0+4.5
5.4+0.7 21.4+ 1.9
19.6+1.7 27.8+2.0
13.0+0.6 36.0+5.1
9.6+1.2 18.5+6.2
26.4+2.7 45.2+2.4
11.4+1.1 23.0+1.4
-7.7+1.0 15.0+2.3
- 12.3+1.0 21.0+2.2
6.0+0.3 13.3+0.7
2.0+0.7 14.9+4.7
16.4+3.3 28.1+0.8
6.6+0.9 17.7+ 1.3
20.3+1.6 18.5+2.5
12.7+7.6 15.5+2.1
-2.2+1.1 2.5+1.2
-0.5+1.4 -2.5+0.3
-0.9+1.2 -4.4+0.3
-7.1+2.4 -11.7+1.4
-10.2+0.1 -10.5+3.0
2.2+4.4 0.4+ 1.2
3.7+ 1.0 3.9+0.9
2.0+1.2 1.5+0.4
-2.5+1.9 -0.7+0.5
-2.9+0.9 1.1+1.0
0.2+ 1.9 0.5+ 1.6
2.2+0.8 0.5+0.4
1.2+1.3 -0.1+3.0
-0.2+2.7 -0.5+1.5
-2.7+0.7 -3.4+1.6
-2.1+2.5 1.5+0.8
-1.1+0.9 1.8+2.0
45.4+2.6 30.4+ 1.0
35.4+6.2 29.3+0.1
49.6+1.4 34.8+4.7
58.0+3.0 35.0+3.7
47.8+3.2 29.2+1.0
*Cells were used after storage in liquid nitrogen.
'Target cells preincubated with or without several concentrations of ActD ranging from 0.1 to 5 igml1 were mixed
with serial dilutions of IFN-activated or untreated PBM effector cells as indicated in a 5.5h NK-chromium release assay
(see Materials and methods). Specific release from ActD pretreated target cells is compared with release from untreated
targets with the release at one effector to target ratio (E:T) taken from the linear portion of the titration curve.
2PBM cells from healthy individuals were used.
3E:T=effector-to-target ratio.
4s.d. =standard deviation oftriplicates given in % specific release.
'IFN=human fibroblast interferon (fi type) used at 300-500Uml- final concentration.
6ActD=Actinomycin D.
7Haematological classification of leukaemia cells: ALL =acute lymphocyte leukaemia;
AML _acute myelocytic leukaemia;
AMML =acute monomyelocytic leukaemia;
CML-BC=chronic myelocytic leukaemia in blast crisis.
Control targets: PBM =peripheral blood mononuclear cells;
PHA-BL =mitogen-induced blast cells.
8Only the one Actinomycin D concentration given was tested.
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Figure 1 Effect of Act D treatment of leukaemia cells from 4 different patients on lysability by IFN-activated
NK cells. Release from untreated targets (0); release from targets pretreated with Actinomycin D (@). (a) Vg
target, Expt. 4; (b) Ri target, Expt. 9; (c) Sc target, Expt. 10; (d) St target, Expt. 12. Effector cell donor Wa.
specific release of 19.8% at an E:T of 80:1.
Additional pretreatment of Vg target cells with
ActD enhanced release to 50.0% at the same E:T
ratio. In terms of lytic units (LU), (1 LU being
defined as the number of effector cells required to
give 15% release), untreated targets required
49.0 x 104 effector cells for 1 LU while ActD treated
cells were lysed to the same extent by only 7.6 x 104
effector cells reflecting a 6.4 fold enhancement of
lysability in this example. Figure ID illustrated that
the ALL-leukaemia cells from donor St could not
be lysed even by IFN activated NK cells. Only after
pretreatment of the ALL cells with ActD was an
efficient killing of these leukaemia cells observed.
Our initial observations on the enhancement of
NK lysis by treatment of leukaemia cells with ActD
were made with leukaemia cell samples stored in
liquid nitrogen. Data from 4 experiments (Expts. 7,
8, 10, 11, Table I) where leukaemia cells from 2
donors were tested, demonstrated that this effect
was a feature of both fresh and cryopreserved
leukaemia cells. Cytotoxicity could be enhanced by
treatment of fresh targets from donor Ri from
19.6% to 27.8% at an E:T ratio of 50:1 (Expt. 7).
With cryopreserved Ri cells the enhancement was
seen as well (13.0 to 36.0% at E:T 40:1, Expt. 8).
With similar data found with leukaemia cells from
donor Sc it was evident that the enhancement of
lysis was not an artefact brough about by liquid
nitrogen-storage of the leukaemic cells. An
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additional finding was that cryopreserved effector
cells could be used in place of freshly isolated killer
cells with the same results (Expts. 5, 6, 8, 11).
With the 4 fresh leukaemias introduced above
(Vg, Ri, Sc, St) and in 4 additional cases (cf. Table
I) enhancement of lysis by ActD pretreatment was
consistently observed. In 6 samples (Su, Hu, Mi,
Rd, Rp and Li) no such effect was detected.
With 2 targets the IFN-treated effector cells were
able to kill untreated leukaemia cells but no further
enhancement was seen after ActD treatment. In the
4 remaining targets no NK lysis was ever obtained
with any regime. In the latter situation the lack of
effect of ActD might be explained by the lack of
any binding between target and effector cells. The
absence of any enhancing effect in the 2 leukaemias
where some lysis and thus target binding was seen
remains, however, unexplained.
In almost all ActD treatment experiments we
took care to test several doses of Actinomycin D
with each target. Figure 2 illustrates the necessity
for this procedure. Enhancement was seen with all
doses from 0. jigml- I to 5 ugml - I with Vg target
whereas enhanced lysis of target Sc was seen only
with doses of 0.1 and 0.2igml-1, while 1.0 and
5jugml-1 resulted in a decreased release compared
to untreated controls in this experiment.
._
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Figure 2 Dose dependence of the Act D effect on two
different leukaemias. Release from leukaemic target Sc
(AML) at E:T ratio, 18:1 (A); release from leukaemia
target Vg (ALL) at E:T ratio, 10:1 (0). In both
experiments effector cells were IFN activated.
The doses found suitable for enhancement of NK
cell-mediated lysis of fresh human leukaemia cells
were lower than the ActD concentrations of
40pgml-1 used by Schlager et al. (1979) for
enhanced complement-dependent lysis of a guinea
pig hepatoma, but they are comparable to the
lugml-l dose used by Kunkel et al. (1981) for the
enhancement of NK cell-mediated lysis of murine
fibroblasts.
The same investigators employed longer drug
pretreatment times of 17-24h. In our hands,
overnight exposure as tested with the Vg target,
reduced the spontaneous release, e.g. from 36 to
20% (data not shown) and made the comparison of
treated and untreated leukaemia cells difficult.
Therefore, we worked throughout the study with a
standard treatment time of 3.5-4h, a procedure
that did not result in a change of spontaneous
release from the targets. For the 6 leukaemia
targets resistant to the susceptibility enhancement
by ActD, however, both longer periods of drug
treatment and higher doses of ActD might have
been effective.
In the 4 leukaemias without any lysis it is
unlikely that the activity of the effector cells was
insufficient, as the IFN-activated PBM assayed in
parallel against K562 targets showed high activity
in these experiments with the specific release always
exceeding 50%. In addition effector cells from donor
Jo, operative in experiments where enhancement of
lysis was seen, were used in several of these
"negative" experiments. Still, we cannot exclude that
effector cells from other donors would have been
able to mediate an enhanced lysis due to ActD
treatment of the target cells since lysis of fresh
leukaemia cells by IFN-activated effectors has been
shown to depend on the effector-target combination
(Moore et al., 1982).
We then asked whether lysis of highly NK
susceptible leukaemia cell lines could be further
enhanced by ActD pretreatment. In 3 independent
experiments (28, 29 and 30, Table I) K562 cells or
Molt4 cells treated with various doses according to
the established regime, did not show an
enhancement but a dose-dependent decrease of
lysability. One might speculate that in vitro cell
lines cannot be enhanced in their susceptibility,
because, they are already maximally lysed, while in
vivo grown tumour cells, under the selective
pressure of NK cells, become resistant and after
drug exposure are susceptible to lysis again. This
theory would be in keeping with the finding of
Collins et al. (1981), who found that in vitro cell
lines with high susceptibility to NK cells became
resistant after in vivo passage.
Additional control targets in our study were
PBM and PHA-blasts (Expt. 23-27, Table I).
Under optimized conditions we were unable to
induce any lysis by ActD pretreatment of these
normal lymphocytes and lymphoblasts. Thus, the
enhancement of NK lysis by ActD appears to be
restricted to malignant cells.512 H.W.L. ZIEGLER-HEITBROCK, J. ERHARDT & G. RIETHMOLLER
The NK cell responsible for lysis of fresh human
chronic leukaemia cells was shown in previous
studies to be identical to the NK cell active against
K562 cell line cells, as demonstrated with cold
target inhibition assays (Pattengale et al., 1982).
Since we could demonstrate in a separate study that
the enhanced lysis of mouse fibrosarcoma cells after
ActD treatment is mediated by human monocytes
(Ziegler-Heitbrock et al., submitted), it was
necessary to analyse what type of effector cell was
active against ActD treated fresh leukaemia cells.
In initial experiments we found that effector cells
non-adherent to nylon wool can mediate enhanced
lysis (data not shown), indicating that the killers
are not monocytes. For further analysis we
employed cold target inhibition experiments with
radio-labelled ActD treated Vg, St and Ri
leukaemia cells as targets and ActD-treated fresh
leukaemia cells, NK sensitive Molt4 and K562 cells
and NK-insensitive P815 cells as unlabelled
inhibitors, together with IFN-treated effector cells.
As shown in Figure 3A inhibition of lysis of ActD-
treated Vg leukaemia cells was most pronounced
with Molt4 cells, followed by the ActD-treated
fresh leukaemia. P815, the NK insensitive mouse
cell line, exerted slight inhibition in this experiment
at the highest inhibitor-to-target ratio, consistent
with a low level of lysis (13.3% at E:T 50:1)
obtained with radio-labeled P815 in the same
experiment. In a second experiment (Figure 3B),
where K562 cells instead of Molt4 were used as
inhibitors along with the ActD-treated Vg cells,
essentially identical results were obtained, with
K562 being superior as an inhibitor to ActD-
treated Vg cells. Cold target inhibition experiments
with ActD-treated radiolabelled St and Ri cells as
targets gave the same type of result. Thus the NK-
sensitive leukaemia cell line cells and ActD-treated
fresh leukaemia cells share target structures and are
lysed by essentially one type of natural killer cell.
This interpretation is consistent with our recent
studies using monoclonal antibodies against NK
cells (Ziegler-Heitbrock et al., in preparation). Our
observations with fresh human leukaemia cells
demonstrate that susceptibility to NK cell-mediated
lysis of a given target is not a constant property,
but can be readily changed by exposure of the
leukaemia cells to ActD. Working with cell lines,
both Gidlund et al. (1981) and Clark et al. (1981)
showed that susceptibility to NK lysis decreased or
increased, when they were treated with inducers of
cell differentiation. Induction of differentiation in
the fresh leukaemic cells studied in this report, is an
unlikely explanation for the observed enhancement
since 4 hours are enough for these leukaemias while
days of exposure were used in the differentiation
induction experiments. At the molecular level,
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Figure 3 Cold target inhibition of cell-mediated lysis
of Act D treated leukaemia cells. IFN-treated effector
cells were admixed with 2-fold serial dilutions of
unlabelled (cold) target cells and ActD-treated 51Cr-
labelled Vg leukaemia cells giving an E:T ratio, 50:1.
The cold inhibitors were ActD-treated Vg cells (0),
P815 (0), K562 (A) and Molt4 (El). Specific release at
E:T ratio 50:1 from Vg cells without addition of
inhibitor cells was 31.3% and 48.6% (Figure 3A) and
38.9% and 53.0% (Figure 3B) for the untreated and the
ActD-treated Vg cells, respectively. Specific release
from P815 targets as assessed in the same experiments
was 13.3% and 16.9% at E:T ratio of 50:1 in the
respective experiments.
Schlager (1982) found that the increased lysis by
cytotoxic T cells of mouse mastocytoma cell line
cells after treatment with mitomycin C correlated
with the cellular synthesis and content of polar
phospholipids, while no such correlation was seen
with DNA, RNA and protein synthesis. The higher
content of polar phospholipids decreases cell
surface charge and this could facilitate
effector:target interaction. In cold target inhibition
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experiments with Vg, Sc and Ri leukaemia cells,
however, we could not demonstrate a higher
inhibitory capacity of the ActD-treated in
comparison with the untreated leukaemia cells.
Data of a representative experiment in Figure 4
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Figure 4 Cold target inhibition of cell-mediated lysis
of untreated and ActD treated leukaemic cells. IFN-
activated effector cells at E:T ratio 35:1 were tested
against 51Cr-labelled untreated (O, 0) and ActD-
treated (El, *) Vg target cells. Serial 2-fold dilutions of
cold Vg inhibitor cells either untreated (open symbols)
or ActD-treated (solid symbols) were added to the
wells.
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show that at an E:T ratio of 35:1 untreated
leukaemic cells are lysed to the extent of 32%
specific lysis while ActD treated leukaemic cells are
lysed to 63%. When these two types of unlabelled
leukaemic cells were added to wells containing
effector and target cells with inhibitor-to-target
ratios of 50:1 to 1.6:1 inhibition occurs for both
untreated and ActD treated cells to the same
degree. These findings indicate that enhanced
binding of effector and target cells is not the
relevant mechanism for the ActD induced-
enhancement of NK lysis.
In this report we demonstrate for the first time a
drug-sensitive reistance to cell-mediated lysis in
fresh human leukaemia cells in allogeneic effector-
target combinations. Studies by Vanky et al. (1980)
demonstrated that lysis of allogeneic but not
autologeous biopsy cells from solid tumours could
be enhanced by IFN pretreatment of the effector
cells. Our data indicate that enhanced lysis after
cytostatic drug treatment of leukaemia cells occurs
in addition to enhancement by IFN treatment and
it might be worthwhile to test autologeous killer
cells in conjunction with drug-treated leukaemia
cells.
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